Loading...
Following FDA approval of tenofovir/FTC as antiretroviral preexposure prophylaxis (PrEP), studies continue to be reported on this intervention. In two recently published papers based on the same domestic trial involving men who have sex with men, researchers examined the safety and tolerability of tenofovoir PrEP and the sexual risk taking of participants.
The randomized, phase II CDC Safety Study involved four arms: delayed and immediate tenofovir PrEP and delayed and immediate placebo; follow-up lasted 24 months after drug initiation. The delayed arms were included to assess changes in risk-taking behaviors associated with taking the study drug. Of 400 participants enrolled, 373 received a study drug at least once and were included in the …